Know Cancer

or
forgot password

A Phase I/II Trial of BAY 43-9006 in Combination With Bevacizumab in Patients With Advanced RenalCancer


Phase 1/Phase 2
18 Years
N/A
Not Enrolling
Both
Kidney Cancer

Thank you

Trial Information

A Phase I/II Trial of BAY 43-9006 in Combination With Bevacizumab in Patients With Advanced RenalCancer


OBJECTIVES:

Primary

- Determine the tolerability and maximum tolerated dose of sorafenib and bevacizumab in
patients with advanced renal cell cancer. (Phase I)

- Determine the progression-free survival of patients treated with this regimen. (Phase
II)

- Determine the median time to progression in patients treated with this regimen. (Phase
II)

- Determine the number and percent of patients with stable disease at 6 months after
treatment with this regimen. (Phase II)

- Determine the objective response rate and duration of objective response in patients
treated with this regimen. (Phase II)

- Determine the number of complete and partial responses in patients treated with this
regimen. (Phase II)

Secondary

- Correlate changes in tumor perfusion and vascular permeability by serial dynamic
contrast-enhanced MRI or arterial spin labeled MRI with antitumor effects of this
regimen and clinical outcome in these patients. (Phase II)

- Determine the effect of this regimen on circulating endothelial cells and progenitors
as an indicator of angiogenic effects in these patients. (Phase II)

- Correlate steady-state trough plasma concentrations of these drugs with toxicity and
clinical activity in these patients. (Phase II)

OUTLINE: This is an open-label, multicenter, phase I dose-escalation study followed by a
phase II study.

- Phase I: Patients receive oral sorafenib twice daily on days 1-28 and bevacizumab IV
over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of
disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of sorafenib and bevacizumab until the
maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at
which 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are
treated at the MTD.

- Phase II: Patients receive oral sorafenib once daily on days 1-28 and bevacizumab IV
over 90 minutes on days 1 and 15 at the MTD in the absence of disease progression or
unacceptable toxicity*.

NOTE: *Patients may remain on protocol if only 1 of the drugs is stopped.

- After completion of study therapy, patients are followed every 3 months for 2 years and
then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 32-58 patients (12-18 for the phase I portion and 20-40 for
the phase II portion) will be accrued for this study within approximately 5-19 months.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed renal cell carcinoma (RCC) of 1 of the
following types*:

- Clear cell

- Papillary (phase I only)

- Chromophobe (phase I only)

- Sarcomatoid (phase I only) NOTE: *Clear cell RCC with < 25% of any other
histology (e.g., papillary, chromophobe, or oncocytic) required for enrollment
in the phase II portion of the study

- Advanced disease

- Measurable disease not curable by standard therapy (for patients in the phase I
portion of the study only)

- Measurable disseminated disease that is not curable by standard radiotherapy or
surgery (for patients in the phase II portion of the study only)

- Has undergone prior nephrectomy, unless 1 of the following is true (for patients in
the phase II portion of the study only):

- Primary tumor ≤ 5 cm

- Extensive liver metastases (i.e., > 30% of liver parenchyma) OR multiple bone
metastases (i.e., > 5) OR extensive extrarenal tumor or unresectable
local/regional tumor extension making nephrectomy a clinically questionable and
unreasonable procedure

- Tumor tissue block available (for patients in the phase II portion of the study only)

- No history or clinical evidence of CNS disease, including primary brain tumor
(history of meningioma allowed), or brain metastasis

- Patients with a history of brain metastasis that have been resected or have had
radiosurgery with no progression for man than 6 months are eligible

PATIENT CHARACTERISTICS:

Age

- 18 and over

Performance status

- ECOG 0-1

Life expectancy

- More than 3 months

Hematopoietic

- Hemoglobin ≥ 9.0 g/dL (transfusion allowed)

- WBC ≥ 3,000/mm^3

- Absolute granulocyte count ≥ 1,200/mm^3

- Platelet count ≥ 100,000/mm^3

- No history of bleeding diathesis or coagulopathy

Hepatic

- Bilirubin ≤ 1.5 times upper limit of normal (ULN)

- AST and ALT ≤ 2.5 times ULN

- INR ≤ 1.5

- aPTT ≤ 1.3 times ULN

Renal

- Creatinine ≤ 1.5 times ULN (2.0 times ULN for patients in the phase II portion of the
study) OR

- Creatinine clearance ≥ 40 mL/min

- Urine protein < 1+ by dipstick OR ≤ 1,000 mg by 24-hour urine collection

Cardiovascular

- No uncontrolled hypertension

- Blood pressure must be ≤ 150/90 mm Hg on a stable antihypertensive regimen

- No clinically significant cardiovascular disease within 1 year prior to study entry

- No myocardial infarction within the past 6 months

- No unstable angina pectoris within the past 6 months

- No New York Heart Association grade II-IV congestive heart failure

- No serious cardiac arrhythmia requiring medication

- No peripheral vascular disease ≥ grade 2 within the past year

- No history of stroke

- No other clinically significant cardiovascular disease

Other

- Not pregnant

- No nursing during and for ≥ 3 months after completion of study treatment

- Negative pregnancy test

- Fertile patients must use effective contraception prior to, during, and for ≥ 3
months after completion of study treatment

- No condition that would preclude ability to swallow pills

- No other malignancy within the past 3 years with the exception of non-melanoma skin
cancer, melanoma in situ, cervical cancer, ductal carcinoma in situ, or lobular
carcinoma in situ (for patients in the phase II portion of the study only)

- No prior malignancy that does not have a very likely cure rate (i.e., approximately
75% or greater) (for patients in the phase II portion of the study only)

- No history of allergic reaction attributed to Chinese hamster ovary cell products,
other recombinant human antibodies, or compounds of similar chemical or biological
composition to sorafenib

- No psychiatric illness or social situation that would preclude study compliance

- No serious non-healing wound, ulcer, or bone fracture

- No history or clinical evidence of uncontrolled seizures

- No significant traumatic injury within the past 28 days

- No ongoing or active infection requiring parenteral antibiotics

- No other uncontrolled illness

- No history of seizures unless controlled with standard medical therapy

PRIOR CONCURRENT THERAPY:

Biologic therapy

- More than 4 weeks since prior immunotherapy

- More than 8 weeks since prior monoclonal antibodies

- No more than 1 prior vaccine or cytokine-based immunotherapy regimen for stage IV
disease (for patients in the phase II portion of the study only)

- No prior vascular endothelial growth factor (VEGF) or VEGF signaling inhibitors

- No prior bevacizumab or sorafenib

- No other prior antiangiogenic therapy (e.g., SU011248, ZD6474, or VEGF Trap)

- Prior thalidomide or interferon alfa as adjuvant therapy or for treatment of stage IV
disease allowed

- No concurrent prophylactic granulocyte or platelet colony-stimulating factors

Chemotherapy

- More than 4 weeks since prior chemotherapy

- No prior chemotherapy regimen for stage IV disease (for patients in the phase II
portion of the study only)

- Prior immunotherapy is not considered chemotherapy

Endocrine therapy

- Not specified

Radiotherapy

- At least 2 weeks since prior radiotherapy and recovered

Surgery

- See Disease Characteristics

- More than 4 weeks since prior major surgical procedure or open biopsy

- No concurrent major surgery

Other

- No prior MAP kinase pathway inhibitors (for patients in the phase II portion of the
study only)

- No prior experimental therapy for advanced RCC (for patients in the phase II portion
of the study only)

- No concurrent or recent (within 7 days of starting study drugs) use of full-dose
anticoagulants or thrombolytic agents

- Concurrent anticoagulants to maintain patency of preexisting, permanent
indwelling IV catheters allowed

- Concurrent warfarin allowed provided INR ≤ 1.5

- No concurrent P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin,
carbamazepine, phenobarbital, rifampin, or Hypericum perforatum [St. John's wort])

- No concurrent combination anti-retroviral therapy for HIV-positive patients

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Maximum Tolerated Dose (MTD) of BAY 43-9006 (Sorafenib)in Combination With Bevacizumab (Phase I)

Outcome Description:

The highest dose in milligrams (mg) of BAY 43-9006 (Sorafenib) in combination with Bevacizumab while maintaining tolerability. Cohorts of 3-6 patients received escalating doses of sorafenib and bevacizumab until the maximum tolerated dose (MTD) was achieved. The MTD is defined as the dose preceding that at which 2 or more of 6 patients experience dose-limiting toxicity during the initial cycle of therapy. DLTs include absolute neutrophil count (ANC) < 500/mm3 for > 7 days, ANC < 1000/mm3 with fever > 101 degrees Fahrenheit, platelet count < 50,000 mm3, and non-hematologic toxicity Common Toxicity Criteria (CTC) >= Grade 3.

Outcome Time Frame:

at 28 days

Safety Issue:

Yes

Principal Investigator

Jeffrey A. Sosman, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Vanderbilt-Ingram Cancer Center

Authority:

United States: Food and Drug Administration

Study ID:

VICC URO 0470

NCT ID:

NCT00126503

Start Date:

May 2005

Completion Date:

January 2012

Related Keywords:

  • Kidney Cancer
  • clear cell renal cell carcinoma
  • recurrent renal cell cancer
  • stage IV renal cell cancer
  • Carcinoma, Renal Cell
  • Kidney Neoplasms

Name

Location

Beth Israel Deaconess Medical CenterBoston, Massachusetts  02215
Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, Pennsylvania  19104-4283
Vanderbilt-Ingram Cancer CenterNashville, Tennessee  37232-6838
Vanderbilt-Ingram Cancer Center - Cool SpringsNashville, Tennessee  37064
Vanderbilt-Ingram Cancer Center at FranklinNashville, Tennessee  37064